Combined-modality treatment for stage IIIa (N2) non-small cell lung cancer: A National Cancer Institute Intergroup study

Research output: Contribution to journalArticlepeer-review

Abstract

Induction chemotherapy plus radiotherapy followed by surgery, evaluated in a number of phase II studies, is an effective treatment for patients with stage IIIA non-small cell lung cancer (NSCLC). The ongoing phase III National Cancer Institute Intergroup study is evaluating concurrent chemotherapy (cisplatin + etoposide)/radiotherapy followed by either surgery or additional radiotherapy followed by 2 additional cycles of chemotherapy in patients with stage IIIA disease. This study will help define the role of surgery and radiotherapy as part of the multimodality therapy of locoregional advanced NSCLC.

Original languageEnglish (US)
Pages (from-to)S71-S74
JournalCancer Chemotherapy and Pharmacology, Supplement
Volume42
StatePublished - Aug 1 1998

Keywords

  • Combined-modality treatment
  • NSCLC
  • Stage IIIA

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Cancer Research

Fingerprint Dive into the research topics of 'Combined-modality treatment for stage IIIa (N<sub>2</sub>) non-small cell lung cancer: A National Cancer Institute Intergroup study'. Together they form a unique fingerprint.

Cite this